Core Insights - A lawsuit has been filed against Metagenomi, Inc. (NASDAQ: MGX) for alleged violations of securities laws, with a deadline for affected investors to act by November 25, 2024 [1][4]. Company Overview - Metagenomi, Inc. completed its initial public offering (IPO) on February 13, 2024, selling approximately 6.25 million shares at $15 per share [3]. - Following the termination of a collaboration agreement with Moderna on May 1, 2024, shares of Metagenomi, Inc. have declined by over 85% [3]. Legal Proceedings - The lawsuit claims that the defendants made materially false and misleading statements regarding the company's business and prospects, seeking to compensate investors who purchased shares during the IPO and suffered losses [4]. - Investors who incurred losses exceeding $100,000 are encouraged to contact the Shareholders Foundation for assistance [2].
Lawsuit Deadline Notice: Metagenomi, Inc. Investors who lost over $100,000 with NASDAQ: MGX shares should contact the Shareholders Foundation